2 No-Brainer Healthcare Stocks to Buy With $500 Right Now
It's one of the top healthcare stocks in my portfolio. If I didn't already own this biotech stock, I wouldn't hesitate to buy ...
Market Whales and Their Recent Bets on CRSP Options
In terms of liquidity and interest, the mean open interest for CRISPR Therapeutics options trades today is 628.14 with a total volume of 1,152.00.
Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Q4 2024 Earnings Call Transcript
Q4 2024 Earnings Call Transcript February 13, 2025 Operator: Good morning, and welcome to Agios’ Fourth Quarter 2024 ...
Bahrain conducts 1st CRISPR-based sickle cell treatment outside U.S.
Bahrain has achieved a medical milestone by successfully treating a patient with sickle cell disease (SCD) using ...
Agios Pharmaceuticals: Liver Toxicity Issues May Threaten Thalassemia Approval (Rating ...
Despite promising Phase 3 results, safety concerns, namely liver injury, have impacted Agios stock and could affect Pyrukund's approval and market adoption. Read the full report here.
Agios' Q4 Loss Wider Than Expected, Pyrukynd Drives Revenues
AGIO reports mixed fourth-quarter 2024 results. Its sole marketed drug, Pyrukynd, drives revenues year over year.
The Week8 天
How public-private partnerships are making bone marrow transplants accessible and affordable
Bone marrow transplantation is a costly procedure. Depending on the type of transplant the rate may vary from ₹7 lakh to ₹50 ...
Crispr Therapeutics Q4 Earnings Review: Ignore The Lack Of Revenues, Buy The Future
Crispr Therapeutics AG has revenue declines but holds strong financials. Promising Sickle Cell therapy & 2025 data readouts ...